Clinical Trials

Aducanumab: FDA “accelerated approval” is conditional

June 7, 2021 — 0 Comments

Clinical Trials

Waiting: the FDA & aducanumab

June 4, 2021 — 0 Comments

Clinical Trials

Donanemab P2 “encouraging”: Really? It Misses Investigators’ Own Target; Cognitive Enhancers Up Next…

May 6, 2021 — 0 Comments

Clinical Trials, Research Strategy

Exercise & The Little Gray Cells in AD? Eye Opening Paper May Refute That…

April 6, 2021 — 0 Comments

Clinical Trials

“Alzheimer’s Germ Quest”: no $1M winner, but 8 candidate germs!? Other Alzheimer $MM Challenges…

March 1, 2021 — 1 Comment

Clinical Trials, Research Strategy

Off BACE: 70 Year Olds Bounce Back From BACE Drug Cognitive Decline?!

February 7, 2021 — 0 Comments

Funding, Research Administration, Research Strategy

Begley: AD Amyloid ‘cabal” thwarted progress toward a cure for decades

January 28, 2021 — 0 Comments

Clinical cases, Clinical Trials

Lilly’s amyloid donanemab in Phase 2; how a neurologist approaches dementia in a man with memory, behavior problems: NEJM CPC 12.31.20

January 13, 2021 — 0 Comments

Research Administration, Research Strategy

Alz at $3B, “DREAM” of therapy?

January 5, 2021 — 0 Comments

Research Strategy

Hacking the brain? Reverse cognitive aging? Blood cells for nerve regeneration?

December 14, 2020 — 2 Comments